Alexion Pharmaceuticals Inc. Initiates Multinational Registration Trials Of Eculizumab As A Potential Treatment For Patients With Relapsing Neuromyelitis Optica (NMO) And Refractory Generalized Myasthenia Gravis (MG)

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals (Nasdaq:ALXN) today announced the initiation of a single, multinational, placebo-controlled trial to evaluate the safety and efficacy of eculizumab (Soliris®) in patients with relapsing neuromyelitis optica (NMO), a life-threatening, ultra-rare neurologic disorder. Alexion also initiated a single, multinational, placebo-controlled trial in patients with refractory generalized myasthenia gravis (MG), another rare and debilitating neurologic disorder.

Help employers find you! Check out all the jobs and post your resume.